GlassScriptPhysician profile
Chandrakant C Desai
NPI 1699726919
$9,591.77
in general payments reported to CMS, 2019-2025
50 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,235 · 2020: $1,247 · 2021: $1,455 · 2022: $1,282 · 2023: $1,120 · 2024: $1,638 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320 · Education: $52.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.99 |
| Education | $52.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,276.49 | 2019-2025 | |
| Eisai INC. | $1,197.32 | 2019-2024 | |
| Ucb, INC. | $1,161.25 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,061.35 | 2019-2024 | Ajovy, Austedo Xr, Austedo |
| Biogen, INC. | $378.55 | 2019-2024 | Tysabri, Vumerity, Avonex |
| Lilly USA, LLC | $372.77 | 2019-2024 | Reyvow, Emgality, Taltz |
| Catalyst Pharmaceuticals, INC. | $314.08 | 2023-2025 | Fycompa |
| Emd Serono, INC. | $289.45 | 2019-2023 | Mavenclad |
| Abbvie INC. | $255.66 | 2021-2025 | Ubrelvy, Qulipta |
| Celgene Corporation | $254.61 | 2021-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $251.56 | 2019-2023 | Rytary |
| Genzyme Corporation | $236.94 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $227.54 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $208.17 | 2023-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $188.21 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandrakant Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.